Assignee
DINGFU BIOTARGET CO LTD
CN·9 granted patents·5 pending applications·19 citations·filing 2013–2021
Top patents by PatentIndex Score
14 records- 0187US11529425B2Immunoconjugates comprising signal regulatory protein alphaDINGFU BIOTARGET CO LTD·Filed 2018·Granted Dec 20, 2022·6 cites·18 claims
- 0287US11357826B2IL-10 EGFR antibody fusion protein and uses thereofDINGFU BIOTARGET CO LTD·Filed 2019·Granted Jun 14, 2022·4 cites·4 claims
- 0384US11845806B2Proteinaceous heterodimer and use thereofDINGFU BIOTARGET CO LTD·Filed 2018·Granted Dec 19, 2023·3 cites·6 claims
- 0478US10471124B2Proteinaceous heterodimer and use thereofDINGFU BIOTARGET CO LTD·Filed 2015·Granted Nov 12, 2019·3 cites·3 claims
- 0575US11987609B2Proteinaceous heterodimer and use thereofDINGFU BIOTARGET CO LTD·Filed 2018·Granted May 21, 2024·1 cites·2 claims
- 0665US10875926B2Fully human antibody against human CD 137DINGFU BIOTARGET CO LTD·Filed 2015·Granted Dec 29, 2020·1 cites·13 claims
- 0765US10624974B2Anti-OX40 antibody and application thereofDINGFU BIOTARGET CO LTD·Filed 2015·Granted Apr 21, 2020·1 cites·6 claims
- 0854US2023241236A1Methods and compositions for cancer treatmentDINGFU BIOTARGET CO LTD·Filed 2021·Application pending·0 cites
- 0951US2023285555A1Preparation specifically bound with cd137 and use thereofDINGFU BIOTARGET CO LTD·Filed 2021·Application pending·0 cites
- 1050US2022356259A1Isolated antigen-binding protein and application thereofDINGFU BIOTARGET CO LTD·Filed 2020·Application pending·0 cites
- 1148US11883503B2Methods and compositions for cancer treatmentDINGFU BIOTARGET CO LTD·Filed 2018·Granted Jan 30, 2024·0 cites·5 claims
- 1248US2022227827A1Proteinaceous heterodimer and use thereofDINGFU BIOTARGET CO LTD·Filed 2020·Application pending·0 cites
- 1345US11795230B2Anti-CD27 antibodies and use thereofDINGFU BIOTARGET CO LTD·Filed 2018·Granted Oct 24, 2023·0 cites·8 claims
- 1435US2015344577A1Agents for treating tumors, use and method thereofDINGFU BIOTARGET CO LTD·Filed 2013·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →